Juvenile exposure to methamphetamine attenuates behavioral and neurochemical responses to methamphetamine in adult rats

Behavioural Brain Research

Volumn 229, Issue 1, 2012, Pages 118-122

  McFadden, Lisa M ^a,b   Carter, Samantha ^a,c   Matuszewich, Leslie ^a  

^a NORTHERN ILLINOIS UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Development; Dopamine; Locomotion; Microdialysis; Stimulants

Indexed keywords

DOPAMINE; METHAMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR CONTROL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; EX VIVO STUDY; FEMALE; IN VIVO STUDY; JUVENILE ANIMAL; LOCOMOTION; MALE; MICRODIALYSIS; NERVE STIMULATION; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; STIMULUS RESPONSE; UPREGULATION;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FEMALE; MALE; METHAMPHETAMINE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84856170120     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.013     Document Type: Article

References (56)

1. Grant P., Bell K.D.S., Paulson J., Rogers K. Evidence of methamphetamine exposure in children removed from clandestine methamphetamine laboratories. Pediatr Emerg Care 2010, 26:10-14.
2. Garcia-Bournissen F., Rokach B., Karaskov T., Koren G. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch Dis Child Fetal Neonatal Ed 2007, 92:F351-F355.
3. Smith L.M., Chang L., Yonekura M.L., Grob C., Osborn D., Ernst T. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology 2001, 57:255-260.
4. Chang L., Cloak C., Jiang C.S., Farnham S., Tokeshi B., Buchthal S., et al. Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage 2009, 48:391-397.
5. Chang L., Smith L.M., LoPresti C., Yonekura M.L., Kuo J., Walot I., et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatr Res: Neuroimaging 2004, 132:95-106.
6. Hser Y.I., Huang D., Brecht M.L., Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis 2008, 27:13-21.
7. Hanson G.R., Fleckenstein A.E. Basic neuropharmacological mechanisms of methamphetamine. Methamphetamine addiction: from basic science to treatment 2009, 30-60. Guildford Press, New York. J.M. Roll, R.A. Rawson, W. Ling, S. Shoptaw (Eds.).
8. Kalivas P.W. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007, 9:389-397.
9. Chang L., Alicata D., Ernst T., Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007, 102:16-32.
10. Crawford C.A., Williams M.T., Newman E.R., McGougall S.A., Vorhees C.V. Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content. Synapse 2003, 48:131-137.
11. Haycock J.W., Becker L.E., Ang L., Furukawa Y., Hornykiewicz O., Kish S.J. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003, 87:574-585.
12. Chen Y.I., Choi J.K., Xu H., Ren J., Andersen S.L., Jenkins B.G. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function. Dev Neurosci 2010, 32:125-138.
13. Jucaite A., Forssberg H., Karlsson P., Halldin C., Farde L. Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study. Neuroscience 2010, 167:104-110.
14. Volz T.J., Farnsworth S.J., Rowley S.D., Hanson G.R., Fleckenstein A.E. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 2009, 63:147-151.
15. Moll G.H., Hause S., Ruther E., Rothenberger A., Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001, 11:15-24.
16. Teicher M.H., Andersen S.L., Hostetter J.C.J. Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Dev Brain Res 1995, 89:167-172.
17. Andersen S.L., Rutstein M., Benzo J.M., Hostetter J.C., Teicher M.H. Sex differences in dopamine receptor overproduction and elimination. Neuropharmacol Neurotoxic 1997, 8:1495-1498.
18. Andersen S.L., Teicher M.H. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000, 24:137-141.
19. Giedd J.N., Snell J.W., Lange N., Rajapakse J.C., Casey B.J., Kozuch P.L., et al. Quantitative magnetic resonance imaging of human brain development: ages 4-18. Cereb Cortex 1996, 6:551-560.
20. Cadet J.L., Krasnova I.N., Ladenheim B., Cai N.S., McCoy M.T., Atianjoh F.E. Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain. Neurotoxicol Res 2009, 15:252-259.
21. Danaceau J.P., Deering C.E., Day J.E., Smeal S.J., Johnson-Davis K.L., Fleckenstein A.E., et al. Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 2007, 559:46-54.
22. Johnson-Davis K.L., Truong J.G., Fleckenstein A.E., Wilkins D.G. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 2004, 309:578-586.
23. Stephans S., Yamamoto B.K. Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 1996, 72:593-600.
24. Dluzen D.E., McDermott J.L., Darvesh A.S. Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity. Neuroscience 2010, 167:985-993.
25. McDaid J., Graham M.P., Napier T.C. Methamphetamine-induced sensitization differentially alters pCREB and DeltaFosB throughout the limbic circuit of the mammalian brain. Mol Pharmacol 2006, 70:2064-2074.
26. Ujike H., Onoue T., Akiyama K., Hamamura T., Otsuki S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 1989, 98:89-92.
27. Shuto T., Kuroiwa M., Hamamura M., Yabuuchi K., Shimazoe T., Watanabe S., et al. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D1 receptor agonist. Neuropharmacology 2006, 50:997.
28. Suzuki H., Shishido T., Watanabe Y., Abe H., Shiragata M., Honda K., et al. Changes of behavior and monoamine metabolites in the rat brain after repeated methamphetamine administration: effects of duration of repeated administration. Prog Neuropsychopharmacol Biol Psychiatry 1997, 21:359-369.
29. McFadden L.M., Yamamoto B.K., Matuszewich L. Alterations in adult behavioral responses to cocaine and dopamine transporters following juvenile exposure to methamphetamine. Behav Brain Res 2011, 216:726-730.
30. Walker Q.D., Nelson C.J., Smith D., Kuhn C.M. Vaginal lavage attenuates cocaine-stimulated activity and establishes place preference in rats. Pharmacol Biochem Behav 2002, 73:743-752.
31. Matuszewich L., Yamamoto B.K. Chronic stress augments the long-term and acute effects of methamphetamine. Neuroscience 2004, 124:637-646.
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
33. Holson R.R., Bowyer J.F., Clausing P., Gough B. Methamphetamine-stimulated striatal dopamine release declines rapidly over time following microdialysis probe insertion. Brain Res 1996, 739:301.
34. Holson R.R., Gazzara R.A., Gough B. Declines in stimulated striatal dopamine release over the first 32h following microdialysis probe insertion: generalization across releasing mechanisms. Brain Res 1998, 808:182-189.
35. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., Carlezon W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 2001, 5:13-14.
36. Mague S.D., Andersen S.L., Carlezon W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 2005, 57:120-125.
37. Carrey N., Wilkinson M. A review of psychostimulant-induced neuroadaptation in developing animals. Neurosci Bull 2011, 27:197-214.
38. Carlezon W.A., Mague S.D., Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 2003, 54:1330-1337.
39. Andersen S.L., Naplerata L., Brenhouse H.C., Sonntag K.C. Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors. Eur J Neurosci 2008, 27:2962-2972.
40. Moll G.H., Mehnert C., Wicker M., Bock N., Rothenberger A., Rüther E., et al. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Dev Brain Res 2000, 119:251-257.
41. Truong J.G., Wilkins D.G., Baudys J., Crouch D.J., Johnson-Davis K.L., Gibb J.W., et al. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther 2005, 314:1087-1092.
42. Schmidt C.J., Gehlert D.R., Peat M.A., Sonsalla P.K., Hanson G.R., Wamsley J.K., et al. Studies on the mechanism of tolerance to methamphetamine. Brain Res 1985, 343:305-313.
43. O'Neil M.L., Kuczenski R., Segal D.S., Cho A.K., Lacan G., Melega W.P. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 2006, 60:465-473.
44. Milesi-Halle A., McMillan D.E., Laurenzana E.M., Byrnes-Blake K.A., Owens S.M. Sex differences in (+)-amphetamine and (+)methamphetamine-induced behavioral responses in male and female Sprague Dawley rats. Pharmacol Biochem Behav 2007, 86:140-149.
45. Dluzen D.E., McDermott J.L. Sex differences in dopamine- and vesicular monoamine-transporter functions: implications for methamphetamine use and neurotoxicity. Ann NY Acad Sci 2008, 1139:140-150.
46. Dluzen D.E., Salvaterra T.J. Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: comparisons with potassium-evoked output and responses in prepubertal mice. Neuroendocrinology 2005, 82:78-86.
47. Milesi-Halle A., Hendrickson H.P., Laurenzana E.M., Gentry W.B., Owens S.M. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol 2005, 209:203-213.
48. Becker J.B. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999, 64:803-812.
49. Castner S.A., Xiao L., Becker J.B. Sex differences in striatal dopamine: in vivo microdialysis and behavioral studies. Brain Res 1993, 610:127-134.
50. Nelson A.M., Larson G.A., Zahniser N.R. Low or high cocaine responding rats differ in striatal extracellular dopamine levels and dopamine transporter number. J Pharmacol Exp Ther 2009, 331:985-997.
51. Allen R.M., Everett C.V., Nelson A.M., Gulley J.M., Zahniser N.R. Low and high locomotor responsiveness to cocaine predicts intravenous cocaine conditioned place preference in male Sprague-Dawley rats. Pharmacol Biochem Behav 2007, 86:37-44.
52. Mandt B.H., Schenk S., Zahniser N.R., Allen R.M. Individual differences in cocaine-induced locomotor activity in male Sprague-Dawley rats and their acquisition of and motivation to self-administer cocaine. Psychopharmacology 2008, 201:195-202.
53. Schuckit M.A. Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry 1994, 151:184-189.
54. Biederman J., Monuteaux M.C., Spencer T., Wilens T.E., MacPherson H.A., Faraone S.V. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008, 165:597-603.
55. Wilens T.E., Faraone S.V., Biederman J., Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
56. Faraone S.V., Wilens T.E. Does stimulant treatment lead to substance use disorders?. J Clin Psychiatry 2003, 64:9-13.